Emcure Pharmaceuticals Ltd.
NSE: EMCURE · Pharmaceuticals
Snapshot
Unlock Emcure Pharmaceuticals Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Emcure Pharmaceuticals Limited is a Pune-based pharmaceutical company that develops, manufactures, and markets a diverse range of healthcare solutions. The company operates across multiple therapeutic areas including gynecology, oncology, anti-infectives, and cardiovascular health.
Business Model
The company generates revenue by developing and selling pharmaceutical products under various established brand names such as Orofer XT and Metpure XL. It focuses on providing affordable healthcare solutions across both domestic and international markets.
- Incorporation Year:1981
Growth Outlook
Growth is driven by the company's extensive portfolio across high-demand therapeutic segments and its commitment to expanding its global footprint. Continued investment in product development remains a core focus for sustaining market competitiveness.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from global health authorities, where non-compliance could lead to product recalls or manufacturing site restrictions.
- Pricing Pressure. Increased competition and government-mandated price controls on essential medicines may impact profit margins in the domestic market.
- R&D Execution. The ability to successfully develop and commercialise new drug formulations is critical to maintaining market share against generic competitors.
- Currency Volatility. As an entity with international operations, the company is exposed to fluctuations in foreign exchange rates that can affect export profitability.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Emcure Pharmaceuticals Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹9,204 Cr
TTM · consolidated
NET PROFIT
₹941 Cr
TTM · consolidated
EPS
₹48.77
TTM · consolidated
RETURN ON EQUITY
20.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
25.6%
TTM · consolidated
P/E
37.0x
Q4 FY26 · consolidated
EV/EBITDA
18.8x
Q4 FY26 · consolidated
EBITDA MARGIN
20.4%
TTM · consolidated
NET PROFIT MARGIN
9.9%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.2x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Emcure Pharmaceuticals Ltd.EMCURE | 29,234 | 36.96 | 18.78 | 16.6% | 20.4% | 20.6% | 25.6% | +32.3% |
Ajanta Pharmaceuticals Ltd.AJANTPHARM | 35,617 | 40.85 | 27.60 | 17.3% | 28.7% | 26.6% | 33.2% | +23.9% |
J.B. Chemicals & Pharmaceuticals Ltd.JBCHEPHARM | 33,423 | 53.22 | 33.03 | 5.9% | 28.1% | 19.6% | 25.0% | +45.5% |
Gland Pharma Ltd.GLAND | 27,558 | 40.56 | 19.84 | 14.5% | 30.3% | 10.9% | 15.0% | +28.3% |
Pfizer Ltd.PFIZER | 21,304 | 23.51 | 15.62 | 36.9% | 43.8% | 21.7% | 28.8% | -12.2% |
Sai Life Sciences Ltd.SAILIFE | 21,073 | 77.96 | 40.43 | — | 31.0% | 15.7% | 20.1% | +59.5% |
As of Q4 FY26
Financials
Emcure Pharmaceuticals Ltd.
NSE: EMCURE · Pharmaceuticals
Snapshot
Unlock Emcure Pharmaceuticals Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Emcure Pharmaceuticals Limited is a Pune-based pharmaceutical company that develops, manufactures, and markets a diverse range of healthcare solutions. The company operates across multiple therapeutic areas including gynecology, oncology, anti-infectives, and cardiovascular health.
Business Model
The company generates revenue by developing and selling pharmaceutical products under various established brand names such as Orofer XT and Metpure XL. It focuses on providing affordable healthcare solutions across both domestic and international markets.
- Incorporation Year:1981
Growth Outlook
Growth is driven by the company's extensive portfolio across high-demand therapeutic segments and its commitment to expanding its global footprint. Continued investment in product development remains a core focus for sustaining market competitiveness.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from global health authorities, where non-compliance could lead to product recalls or manufacturing site restrictions.
- Pricing Pressure. Increased competition and government-mandated price controls on essential medicines may impact profit margins in the domestic market.
- R&D Execution. The ability to successfully develop and commercialise new drug formulations is critical to maintaining market share against generic competitors.
- Currency Volatility. As an entity with international operations, the company is exposed to fluctuations in foreign exchange rates that can affect export profitability.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Emcure Pharmaceuticals Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹9,204 Cr
TTM · consolidated
NET PROFIT
₹941 Cr
TTM · consolidated
EPS
₹48.77
TTM · consolidated
RETURN ON EQUITY
20.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
25.6%
TTM · consolidated
P/E
37.0x
Q4 FY26 · consolidated
EV/EBITDA
18.8x
Q4 FY26 · consolidated
EBITDA MARGIN
20.4%
TTM · consolidated
NET PROFIT MARGIN
9.9%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.2x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26